What is HC Wainwright's Forecast for SRPT FY2024 Earnings?

Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) - Research analysts at HC Wainwright raised their FY2024 earnings per share (EPS) estimates for shares of Sarepta Therapeutics in a research report issued on Wednesday, January 15th. HC Wainwright analyst M. Kapoor now forecasts that the biotechnology company will post earnings of $2.68 per share for the year, up from their previous forecast of $2.30. HC Wainwright currently has a "Sell" rating and a $75.00 target price on the stock. The consensus estimate for Sarepta Therapeutics' current full-year earnings is $2.17 per share. HC Wainwright also issued estimates for Sarepta Therapeutics' Q4 2024 earnings at $1.91 EPS, Q2 2025 earnings at $2.69 EPS, Q3 2025 earnings at $2.78 EPS and FY2025 earnings at $10.75 EPS.

Several other equities research analysts have also recently commented on the stock. Piper Sandler cut their price objective on shares of Sarepta Therapeutics from $200.00 to $182.00 and set an "overweight" rating on the stock in a research report on Wednesday, November 27th. Royal Bank of Canada restated an "outperform" rating and issued a $182.00 price target on shares of Sarepta Therapeutics in a report on Monday, October 21st. Cantor Fitzgerald raised Sarepta Therapeutics from a "neutral" rating to an "overweight" rating and upped their price objective for the stock from $152.00 to $167.00 in a research report on Thursday, November 7th. Jefferies Financial Group initiated coverage on Sarepta Therapeutics in a research report on Monday, October 21st. They issued a "buy" rating and a $165.00 target price on the stock. Finally, Evercore ISI cut their target price on Sarepta Therapeutics from $179.00 to $170.00 and set an "outperform" rating on the stock in a research note on Thursday, November 7th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating, nineteen have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $178.71.

Sarepta Therapeutics Stock Up 0.8 %

SRPT traded up $0.94 during trading on Friday, reaching $118.00. The company had a trading volume of 649,119 shares, compared to its average volume of 788,565. The business's fifty day moving average price is $121.68 and its 200 day moving average price is $129.97. The company has a debt-to-equity ratio of 0.93, a current ratio of 3.84 and a quick ratio of 3.03. Sarepta Therapeutics has a 12 month low of $102.15 and a 12 month high of $173.25. The company has a market cap of $11.27 billion, a P/E ratio of 94.40 and a beta of 0.77.

Institutional Investors Weigh In On Sarepta Therapeutics

Several hedge funds have recently bought and sold shares of SRPT. Nisa Investment Advisors LLC increased its stake in shares of Sarepta Therapeutics by 23.1% during the fourth quarter. Nisa Investment Advisors LLC now owns 1,317 shares of the biotechnology company's stock worth $160,000 after purchasing an additional 247 shares during the period. MassMutual Private Wealth & Trust FSB increased its position in Sarepta Therapeutics by 169.6% during the 4th quarter. MassMutual Private Wealth & Trust FSB now owns 248 shares of the biotechnology company's stock worth $30,000 after buying an additional 156 shares during the period. UMB Bank n.a. lifted its holdings in shares of Sarepta Therapeutics by 36.0% during the fourth quarter. UMB Bank n.a. now owns 521 shares of the biotechnology company's stock worth $63,000 after buying an additional 138 shares in the last quarter. Smith Salley Wealth Management bought a new stake in shares of Sarepta Therapeutics in the fourth quarter valued at about $889,000. Finally, Park Avenue Securities LLC bought a new stake in shares of Sarepta Therapeutics in the fourth quarter valued at about $205,000. 86.68% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other news, Director Hans Lennart Rudolf Wigzell sold 10,500 shares of the firm's stock in a transaction dated Thursday, December 12th. The shares were sold at an average price of $124.84, for a total transaction of $1,310,820.00. Following the completion of the sale, the director now owns 22,840 shares in the company, valued at approximately $2,851,345.60. This trade represents a 31.49 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Kathryn Jean Boor sold 1,636 shares of Sarepta Therapeutics stock in a transaction dated Thursday, December 5th. The stock was sold at an average price of $125.55, for a total transaction of $205,399.80. Following the sale, the director now directly owns 5,880 shares of the company's stock, valued at $738,234. The trade was a 21.77 % decrease in their position. The disclosure for this sale can be found here. Company insiders own 7.70% of the company's stock.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.